HYUNDAI FEED Inc Asset Resilience Ratio
HYUNDAI FEED Inc asset resilience ratio. HYUNDAI FEED Inc (016790) has an Asset Resilience Ratio of 11.71% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 016790 defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of HYUNDAI FEED Inc (2015–2024)
Asset resilience ratio of HYUNDAI FEED Inc from 2015 to 2024. This chart shows how HYUNDAI FEED Inc's Asset Resilience Ratio has changed over time. Read how much debt does HYUNDAI FEED Inc carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down HYUNDAI FEED Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see 016790 current and non-current assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩12.36 Billion | 11.71% |
| Total Liquid Assets | ₩12.36 Billion | 11.71% |
Asset Resilience Insights
- Moderate Liquidity: HYUNDAI FEED Inc has 11.71% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
HYUNDAI FEED Inc Industry Peers by Asset Resilience Ratio
Compare HYUNDAI FEED Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
The Magnum Ice Cream Company N.V.
AS:MICC |
Packaged Foods | 0.11% |
|
Unibel S.A
PA:UNBL |
Packaged Foods | 0.24% |
|
JiangXi Tianxin Pharm Co Ltd
SHG:603235 |
Packaged Foods | 4.40% |
|
Sanquan Food Co Ltd
SHE:002216 |
Packaged Foods | 13.01% |
|
JinJian Cereals Industry Co Ltd
SHG:600127 |
Packaged Foods | 0.04% |
|
Beijing Sanyuan Foods Co Ltd
SHG:600429 |
Packaged Foods | 0.10% |
|
Kri-Kri Milk Industry S.A
AT:KRI |
Packaged Foods | 1.34% |
|
Ridley Corporation Ltd
AU:RIC |
Packaged Foods | 0.27% |
HYUNDAI FEED Inc Asset Resilience Ratio by Year (2015–2024)
HYUNDAI FEED Inc asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for HYUNDAI FEED Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 9.40% | ₩11.00 Billion ≈ $7.45 Million |
₩116.98 Billion ≈ $79.28 Million |
+8.94pp |
| 2023-12-31 | 0.46% | ₩500.00 Million ≈ $338.84K |
₩108.36 Billion ≈ $73.43 Million |
-2.08pp |
| 2022-12-31 | 2.55% | ₩6.91 Billion ≈ $4.68 Million |
₩271.27 Billion ≈ $183.84 Million |
-3.21pp |
| 2021-12-31 | 5.75% | ₩5.39 Billion ≈ $3.66 Million |
₩93.77 Billion ≈ $63.55 Million |
-8.57pp |
| 2020-12-31 | 14.33% | ₩14.07 Billion ≈ $9.53 Million |
₩98.21 Billion ≈ $66.55 Million |
+12.11pp |
| 2019-12-31 | 2.21% | ₩2.15 Billion ≈ $1.46 Million |
₩97.38 Billion ≈ $65.99 Million |
-6.09pp |
| 2018-12-31 | 8.30% | ₩7.81 Billion ≈ $5.29 Million |
₩94.05 Billion ≈ $63.74 Million |
-10.90pp |
| 2017-12-31 | 19.20% | ₩16.29 Billion ≈ $11.04 Million |
₩84.84 Billion ≈ $57.49 Million |
+5.98pp |
| 2016-12-31 | 13.22% | ₩10.95 Billion ≈ $7.42 Million |
₩82.82 Billion ≈ $56.13 Million |
+2.82pp |
| 2015-12-31 | 10.40% | ₩11.17 Billion ≈ $7.57 Million |
₩107.39 Billion ≈ $72.78 Million |
-- |
About HYUNDAI FEED Inc
HYUNDAI FEED Inc. engages in the manufacture and sale of formulated feed. Its primary products include poultry and pig feed. The company also engages in the biopharmaceutical business. In addition, it focuses on the development and commercialization of immunotherapies for cancer. Further, the company's lead product includes oregovomab, an immunotherapy for ovarian cancer. Additionally, it is invo… Read more